Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada

Cost Effectiveness and Resource Allocation

Research

Mitchell Levine¹  Colin Chalk²  Kathryn Gaebel³  Kaitryn Campbell⁴  Gord Blackhouse⁴  Nazila Assasi⁴  Feng Xie⁵  Ron Goeree⁵  Daria O'Reilly⁵  Jean-Eric Tarride⁵ 

[1] Department of Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, Ontario, Canada;Centre for Evaluation of Medicines, St. Joseph's Healthcare, Hamilton, Ontario, Canada;Department of Neurology and Neurosurgery, McGill University, Montréal, Québec, Canada;PATH Research Institute, McMaster University, Hamilton, Ontario, Canada;Centre for Evaluation of Medicines, St. Joseph's Healthcare, Hamilton, Ontario, Canada;PATH Research Institute, McMaster University, Hamilton, Ontario, Canada;Department of Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, Ontario, Canada;PATH Research Institute, McMaster University, Hamilton, Ontario, Canada;Department of Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, Ontario, Canada;Centre for Evaluation of Medicines, St. Joseph's Healthcare, Hamilton, Ontario, Canada;

关键词: Corticosteroid Treatment;    Quality Adjust Life Year;    Probabilistic Sensitivity Analysis;    Chronic Inflammatory Demyelinating Polyneuropathy;    IVIG Treatment;   

DOI  :  10.1186/1478-7547-8-14

 received in 2009-11-27, accepted in 2010-06-17,  发布年份 2010

来源: Springer

【 摘 要 】

ObjectivesIntravenous immunoglobulin (IVIG) has demonstrated improvement in chronic inflammatory demyelinating polyneuropathy (CIDP) patients in placebo controlled trials. However, IVIG is also much more expensive than alternative treatments such as corticosteroids. The objective of the paper is to evaluate, from a Canadian perspective, the cost-effectiveness of IVIG compared to corticosteroid treatment of CIDP.MethodsA markov model was used to evaluate the costs and QALYs for IVIG and corticosteroids over 5 years of treatment for CIDP. Patients initially responding to IVIG could remain a responder or relapse every 12 week model cycle. Non-responding IVIG patients were assumed to be switched to corticosteroids. Patients on corticosteroids were at risk of a number of adverse events (fracture, diabetes, glaucoma, cataract, serious infection) in each cycle.ResultsOver the 5 year time horizon, the model estimated the incremental costs and QALYs of IVIG treatment compared to corticosteroid treatment to be $124,065 and 0.177 respectively. The incremental cost per QALY gained of IVIG was estimated to be $687,287. The cost per QALY of IVIG was sensitive to the assumptions regarding frequency and dosing of maintenance IVIG.ConclusionsBased on common willingness to pay thresholds, IVIG would not be perceived as a cost effective treatment for CIDP.

【 授权许可】

CC BY   
© Blackhouse et al; licensee BioMed Central Ltd. 2010